| Jacoby, Meagan |
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation |
|
|
| Recruiting | 2 | 60 | US | Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis | Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc. | Acute Myeloid Leukemia | 07/26 | 07/26 | | |
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant |
|
|
| Withdrawn | 2 | 35 | NA | Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron | Washington University School of Medicine, Karyopharm Therapeutics Inc | Multiple Myeloma, Myeloma-Associated Amyloidosis | 01/27 | 01/27 | | |
NCT04331119: Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas |
|
|
| Active, not recruiting | 2 | 17 | US | Duvelisib, Copiktra, Peripheral blood draw | Washington University School of Medicine, SecuraBio | T-Cell Lymphoma | 07/26 | 07/26 | | |
NCT03068819: Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant |
|
|
| Recruiting | 1/2 | 110 | US | CIML NK Cell Infusion, CD3+ T Cell Product Infusion | Washington University School of Medicine, National Cancer Institute (NCI), Wugen, Inc., Children's Discovery Institute | Acute Myeloid Leukemia | 10/28 | 10/28 | | |
NCT04742634: Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant |
|
|
| Recruiting | 1/2 | 126 | US | DEC-C, decitabine + cedazuridine, ASTX727, INQOVI®, MyeloSeq-HD | Washington University School of Medicine, Taiho Oncology, Inc. | Myelodysplastic Syndromes | 11/33 | 11/33 | | |
NCT01913951: Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes |
|
|
| Completed | 1 | 35 | US | vosaroxin, voreloxin, Azacitidine, Vidaza, Ladakamycin | Washington University School of Medicine, Sunesis Pharmaceuticals | Myelodysplastic Syndromes | 12/16 | 04/24 | | |
|
|
NCT03572764: CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome |
|
|
| Active, not recruiting | 1 | 20 | US | CPX-351, Vyxeos™, Daunorubicin and cytarabine, Research skin biopsy, Research blood draw, Research bone marrow aspirate | Washington University School of Medicine, Jazz Pharmaceuticals | Myelodysplastic Syndromes | 11/21 | 03/27 | | |
NCT03770429: AZD6738 for Patients With Progressive MDS or CMML |
|
|
| Recruiting | 1 | 52 | US | AZD6738 | Massachusetts General Hospital, AstraZeneca | Leukemia, Myelodysplastic Syndrome | 05/24 | 05/25 | | |
NCT04006652: ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients |
|
|
| Terminated | 1 | 4 | US | ApoGraft | Washington University School of Medicine, Cellect Biotechnology | Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant | 12/22 | 12/22 | | |
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Completed | 1 | 55 | US | Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile | Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI) | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease | 04/24 | 05/24 | | |
NCT06538181: Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome |
|
|
| Not yet recruiting | 1 | 15 | US | Pacritinib | Washington University School of Medicine, Swedish Orphan Biovitrum | E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome, VEXAS, Vexas Syndrome | 02/27 | 01/29 | | |
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Recruiting | 1 | 49 | US | Ruxolitinib, Jakafi | Washington University School of Medicine, Incyte Corporation | Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease | 09/26 | 12/26 | | |
NCT04263181: AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration |
|
|
| Recruiting | N/A | 165 | US | Peripheral blood draw, Bone marrow aspirate, Buccal swab | Washington University School of Medicine, Notable Labs | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 01/25 | 01/25 | | |
| Noland, Jill |
| No trials found |
